<table border="1"><tr><th>Trade names</th><td>Intelence</td></tr><tr><th>AHFS/Drugs.com</th><td>Monograph</td></tr><tr><th>MedlinePlus</th><td>a608016</td></tr><tr><th>License data</th><td>EU |  EMA | by INN | US | FDA: Etravirine</td></tr><tr><th>Pregnancy | category</th><td>AU |  B1</td></tr><tr><th>Routes of | administration</th><td>Oral</td></tr><tr><th>ATC code</th><td>J05AG04 ( | WHO | )</td></tr><tr><th>Legal status</th><td>AU |  S4 (Prescription only) | CA | : Schedule VI | UK |  POM (Prescription only) | US |  ℞-only</td></tr><tr><th>Protein binding</th><td>99.9%</td></tr><tr><th>Metabolism</th><td>Hepatic (CYP3A4, CYP2C9 &amp; CYP2C19-mediated)</td></tr><tr><th>Elimination | half-life</th><td>41±20 hours</td></tr><tr><th>Excretion</th><td>Faeces (93.7%), urine (1.2%)</td></tr><tr><th>Identifiers</th><td>IUPAC name | 4-[6-Amino-5-bromo-2-[(4-cyanophenyl)amino] pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile</td></tr><tr><th>CAS Number</th><td>269055-15-4</td></tr><tr><th>PubChem | CID</th><td>193962</td></tr><tr><th>DrugBank</th><td>DB06414</td></tr><tr><th>ChemSpider</th><td>168313</td></tr><tr><th>UNII</th><td>0C50HW4FO1</td></tr><tr><th>KEGG</th><td>D04112</td></tr><tr><th>ChEMBL</th><td>ChEMBL308954</td></tr><tr><th>NIAID ChemDB</th><td>105156</td></tr><tr><th>PDB ligand</th><td>65B ( | PDBe | , | RCSB PDB | )</td></tr><tr><th>CompTox Dashboard | ( | EPA | )</th><td>DTXSID30181412</td></tr><tr><th>ECHA InfoCard</th><td>100.207.546</td></tr><tr><th>Formula</th><td>C | 20 | H | 15 | Br | N | 6 | O</td></tr><tr><th>Molar mass</th><td>435.285 |  g·mol | −1</td></tr><tr><th>3D model (JSmol)</th><td>Interactive image</td></tr></table>